{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:18Z","timestamp":1787027778319,"version":"build-2736575974"},"reference-count":121,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Glioblastoma (GBM) is the most common and aggressive primary brain tumor, characterized by poor prognosis and a median survival of 12\u201318 months despite standard therapies such as surgery, radiation, and temozolomide chemotherapy. Its high cellular heterogeneity, along with complex mechanisms of therapy resistance, presents significant challenges for effective treatment. Conventional systemic chemotherapy is limited by the blood\u2013brain barrier (BBB), systemic toxicity, and insufficient drug penetration into the tumor microenvironment. Emerging therapeutic strategies aim to overcome these barriers through novel chemotherapeutic agents, targeted therapies, immunotherapies, and smart drug delivery systems. Endovascular drug delivery, particularly super-selective intra-arterial cerebral infusion (SSIACI), offers a minimally invasive approach to directly target the tumor vasculature, potentially increasing drug concentration at the tumor site while reducing systemic exposure. Complementary techniques, such as MR-guided focused ultrasound, hyperosmotic disruption, and nanoparticle-based carriers, are being explored to enhance BBB penetration and retention of therapeutics within the tumor. Ongoing clinical trials and translational studies provide insights into optimizing these approaches, with future directions focused on precision medicine, biomarker-driven patient selection, and combination therapies. Integrating endovascular strategies with innovative chemotherapies and immunotherapies may transform GBM management, but further research is required to establish their efficacy and safety in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers18142278","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:05:07Z","timestamp":1784163907000},"page":"2278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-0268","authenticated-orcid":false,"given":"Zahra","family":"Hasanpour-Segherlou","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8417-7052","authenticated-orcid":false,"given":"Abdolreza","family":"Alikhani","sequence":"additional","affiliation":[{"name":"Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7333-0408","authenticated-orcid":false,"given":"Luca","family":"Bertola","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Rupp","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Haghighi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6629-6820","authenticated-orcid":false,"given":"Jerick","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Medicine, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0433-2139","authenticated-orcid":false,"given":"Clayton","family":"Rawson","sequence":"additional","affiliation":[{"name":"College of Medicine, Noorda College of Osteopathic Medicine, Provo, UT 84604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5824-7343","authenticated-orcid":false,"given":"Andrea","family":"Baloi","sequence":"additional","affiliation":[{"name":"Victor Babes University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemehsadat","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Pahlevani","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jamaica Hospital Medical Center, New York City, NY 11418, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-4080","authenticated-orcid":false,"given":"Brandon","family":"Lucke-Wold","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and Other Primary Brain Malignancies in Adults: A Review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/neuonc\/noac198","article-title":"National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11060-018-03015-9","article-title":"Prevalence of symptoms in glioma patients throughout the disease trajectory: A systematic review","volume":"140","author":"Snijders","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"P\u00f6hlmann, J., Weller, M., Marcellusi, A., Grabe-Heyne, K., Krott-Coi, L., Rabar, S., and Pollock, R.F. (2024). High costs, low quality of life, reduced survival, and room for improving treatment: An analysis of burden and unmet needs in glioma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1368606"},{"key":"ref_8","first-page":"428","article-title":"A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States","volume":"25","author":"Norden","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jang, H.J., and Park, J.W. (2025). Microenvironmental Drivers of Glioma Progression. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052108"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/neuros\/nyaa305","article-title":"\u201cZooming in\u201d on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing","volume":"88","author":"Khalafallah","year":"2021","journal-title":"Neurosurgery"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tang, J., Amin, M.A., and Campian, J.L. (2025). Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. Cells, 14.","DOI":"10.20944\/preprints202503.1215.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"C1045","DOI":"10.1152\/ajpcell.00344.2024","article-title":"Hunting glioblastoma recurrence: Glioma stem cells as retrospective targets","volume":"328","author":"Emir","year":"2025","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"218216","DOI":"10.1016\/j.canlet.2025.218216","article-title":"Tumor microenvironment in glioblastoma: The central role of the hypoxic-necrotic core","volume":"639","author":"Bayona","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10238-025-01631-0","article-title":"Emerging therapeutic strategies in glioblastsoma: Drug repurposing, mechanisms of resistance, precision medicine, and technological innovations","volume":"25","author":"Anwer","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: Current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, Y., Chen, Y., Cai, K., Qin, Y., Wang, X., Zhang, B., Shi, L., He, Z., Wang, J., and Long, J. (2025). Interactions between glioblastoma and myeloid cells. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1632122"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, M.A., Parveen, F., Ataide, J.A., Rajmalani, B.A., and Torchilin, V.P. (2023). Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers, 15.","DOI":"10.3390\/cancers15072116"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.wneu.2019.05.205","article-title":"Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma","volume":"129","author":"Mooney","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2017.01.018","article-title":"Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials","volume":"111","author":"Lombardi","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/cns.15.8","article-title":"Use of bevacizumab in recurrent glioblastoma","volume":"4","author":"Ghiaseddin","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma","volume":"5","author":"Agarwala","year":"2000","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood\u2013tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neurol.2023.03.013","article-title":"Overcoming the blood brain barrier in glioblastoma: Status and future perspective","volume":"179","author":"Ahmed","year":"2023","journal-title":"Rev. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: An updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/362652a0","article-title":"Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage","volume":"362","author":"Branch","year":"1993","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-20-0319","article-title":"Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma","volume":"20","author":"Nogales","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_31","first-page":"299","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gonzalez Castro, L.N., and Santagata, S. (2026). Antibody-drug conjugates for primary brain tumors. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1811494"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11060-025-05248-x","article-title":"Emerging therapies for glioblastoma","volume":"176","author":"Sarfraz","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","article-title":"Strategies to advance translational research into brain barriers","volume":"7","author":"Neuwelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3340\/jkns.2018.0180","article-title":"Magnetic Resonance-Guided Focused Ultrasound: Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening","volume":"62","author":"Lee","year":"2019","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","article-title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): A multicentre, open-label, phase 1\/2 trial","volume":"26","author":"Woodworth","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","article-title":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: A phase 1 trial","volume":"24","author":"Sonabend","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/neurintsurg-2021-018190","article-title":"Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors","volume":"14","author":"Chen","year":"2022","journal-title":"J. NeuroInterv. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3174\/ajnr.A8902","article-title":"A Report from the Inaugural Society of NeuroInterventional Surgery Neurointerventional Oncology Summit","volume":"47","author":"Young","year":"2026","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Paolani, G., Minosse, S., Strolin, S., Santoro, M., Pucci, N., Di Giuliano, F., Garaci, F., Oddo, L., Toumia, Y., and Guida, E. (2025). Intra-Arterial Super-Selective Delivery of Yttrium-90 for the Treatment of Recurrent Glioblastoma: In Silico Proof of Concept with Feasibility and Safety Analysis. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17030345"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425247.2020.1698544","article-title":"Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier","volume":"17","author":"Tosi","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/pharmaceutics6040557","article-title":"Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier","volume":"6","author":"Georgieva","year":"2014","journal-title":"Pharmaceutics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/jnis-2025-024057","article-title":"Safety and efficacy of selective and superselective intra-arterial cerebral infusion with blood-brain barrier disruption for glioma: A systematic review and meta-analysis","volume":"18","author":"Ferreira","year":"2026","journal-title":"J. NeuroInterv. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"105210","DOI":"10.1016\/j.critrevonc.2026.105210","article-title":"Efficacy of intra-arterial chemotherapy across intracranial tumors: A systematic review and meta-analysis","volume":"221","author":"Rahmanipour","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gahide, G., Vendrell, J.F., Massicotte-Tisluck, K., Caux, S., Deschamps, S., No\u00ebl-Lamy, M., Belzile, F., Roy, L.O., and Fortin, D. (2025). Safety of Cerebral Intra-Arterial Chemotherapy for the Treatment of Malignant Brain Tumours. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020524"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11060-026-05463-0","article-title":"From barrier to bridge: A scoping review on the methods, clinical efficacy, and safety of blood-brain barrier disruption in treating high-grade glioma","volume":"177","author":"Dufault","year":"2026","journal-title":"J. Neurooncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41416-025-03325-6","article-title":"Efficacy and safety of low- and high-intensity focused ultrasound in glioblastoma: A systematic review of preclinical and clinical studies","volume":"134","author":"Alrashidi","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: A phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-025-05305-5","article-title":"Modulating the glioma microenvironment with laser interstitial thermal therapy: Mechanisms and therapeutic implications","volume":"176","author":"Vargas","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/neuonc\/noag080","article-title":"Laser Interstitial Thermal Therapy Enhances Bidirectional Blood-Brain Barrier Permeability in Glioblastoma","volume":"28","author":"Cleary","year":"2026","journal-title":"Neuro Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/neuonc\/noae087","article-title":"Consensus review on strategies to improve delivery across the blood-brain barrier including focused ultrasound","volume":"26","author":"Piper","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_61","first-page":"571560","article-title":"Combined Docetaxel-Loaded Perfluorocarbon Nanodroplets with Ultrasound-Mediated Blood-Brain Barrier Disruption for Effective Glioblastoma Treatment in Mice Model","volume":"21","author":"Desgranges","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Huang, R., Boltze, J., and Li, S. (2020). Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: A Systematic Review. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01443"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11060-015-1846-6","article-title":"Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?","volume":"124","author":"Joshi","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_64","first-page":"2338","article-title":"Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide","volume":"53","author":"Schuster","year":"1993","journal-title":"Cancer Res."},{"key":"ref_65","first-page":"3803","article-title":"Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats","volume":"55","author":"Kurpad","year":"1995","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(04)15697-3","article-title":"Endovascular treatment of cerebrovascular diseases and intracranial neoplasms","volume":"363","author":"Qureshi","year":"2004","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/neurintsurg-2019-015137","article-title":"Advances in endovascular neuro-oncology: Endovascular selective intra-arterial (ESIA) infusion of targeted biologic therapy for brain tumors","volume":"12","author":"Srinivasan","year":"2020","journal-title":"J. NeuroInterv. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kappel, A.D., Jha, R., Guggilapu, S., Smith, W.J., Feroze, A.H., Dmytriw, A.A., Vicenty-Padilla, J., Alcedo Guardia, R.E., Gessler, F.A., and Patel, N.J. (2024). Endovascular Applications for the Management of High-Grade Gliomas in the Modern Era. Cancers, 16.","DOI":"10.3390\/cancers16081594"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0271678X15615875","article-title":"Predicting and optimizing the territory of blood-brain barrier opening by superselective intra-arterial cerebral infusion under dynamic susceptibility contrast MRI guidance","volume":"36","author":"Janowski","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Latulippe, J., Roy, L.O., Gobeil, F., and Fortin, D. (2025). Optimization of Intra-Arterial Administration of Chemotherapeutic Agents for Glioblastoma in the F98-Fischer Glioma-Bearing Rat Model. Biomolecules, 15.","DOI":"10.3390\/biom15030421"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1010683128853","article-title":"Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: Experience in 100 procedures","volume":"51","author":"Qureshi","year":"2001","journal-title":"J. Neurooncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/cncr.21112","article-title":"Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: The Sherbrooke experience","volume":"103","author":"Fortin","year":"2005","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2008.19.3789","article-title":"Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: A multi-institutional experience","volume":"27","author":"Angelov","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1148\/radiol.2272012071","article-title":"Neurologic complications of cerebral angiography: Prospective analysis of 2,899 procedures and review of the literature","volume":"227","author":"Willinsky","year":"2003","journal-title":"Radiology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1148\/radiol.11081489","article-title":"Transcatheter intraarterial therapies: Rationale and overview","volume":"259","author":"Lewandowski","year":"2011","journal-title":"Radiology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nec.2012.01.008","article-title":"Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: A technical case series","volume":"23","author":"Shin","year":"2012","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y","article-title":"Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors","volume":"88","author":"Doolittle","year":"2000","journal-title":"Cancer"},{"key":"ref_78","first-page":"183","article-title":"Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme","volume":"9","author":"Burkhardt","year":"2011","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Pinkiewicz, M., Pinkiewicz, M., Walecki, J., and Zawadzki, M. (2022). A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.950167"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: Structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.wneu.2011.05.056","article-title":"Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival","volume":"77","author":"Burkhardt","year":"2012","journal-title":"World Neurosurg."},{"key":"ref_82","first-page":"145","article-title":"Superselective intraarterial cerebral infusion of bevacizumab: A revival of interventional neuro-oncology for malignant glioma","volume":"8","author":"Riina","year":"2009","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Duerinck, J., Tuyaerts, S., Movahedi, K., and Neyns, B. (2023). Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention\u2014current status and future perspectives. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1183641"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3171\/2021.3.PEDS20738","article-title":"Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: Results of a phase I trial","volume":"28","author":"McCrea","year":"2021","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnis-2025-023068","article-title":"Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood-brain barrier disruption in newly diagnosed or recurrent glioblastoma: Technical insights and clinical outcomes from a single-center experience","volume":"18","author":"Ferreira","year":"2026","journal-title":"J. NeuroInterv. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.wneu.2019.07.137","article-title":"Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response","volume":"131","author":"Faltings","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3171\/jns.1992.76.5.0772","article-title":"A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma","volume":"76","author":"Shapiro","year":"1992","journal-title":"J. Neurosurg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000346580","article-title":"Intra-arterial chemotherapy is not superior to intravenous chemotherapy for malignant gliomas: A systematic review and meta-analysis","volume":"70","author":"Chen","year":"2013","journal-title":"Eur. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3109\/02688697.2013.877122","article-title":"The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma","volume":"28","author":"Theodotou","year":"2014","journal-title":"Br. J. Neurosurg."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rechberger, J.S., Thiele, F., and Daniels, D.J. (2021). Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111885"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-021-03851-2","article-title":"Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: A phase I\/II clinical trial","volume":"155","author":"Patel","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jnci\/87.24.1884","article-title":"Evaluating glioma therapies: Modeling treatments and predicting outcomes","volume":"87","author":"Kirby","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Sainatham, C., Yadav, D., Dilli Babu, A., Tallapalli, J.R., Kanagala, S.G., Filippov, E., Murillo Chavez, F., Ahmed, N., and Lutfi, F. (2024). The current socioeconomic and regulatory landscape of immune effector cell therapies. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1462307"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ma, P., Li, Y., Gu, Y., Zeng, H., Xiang, H., Cao, Z., Han, Y., Cui, Y., and Liu, H. (2025). Advances and challenges in novel drug delivery systems for glioma therapy. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1655241"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/neuonc\/noad036","article-title":"A critical analysis of neuro-oncology clinical trials","volume":"25","author":"Kim","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-022-04039-y","article-title":"Analysis of factors leading to early termination in glioblastoma-related clinical trials","volume":"158","author":"Shah","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/0115665232306205240419091414","article-title":"Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines","volume":"25","author":"Rotte","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e012308","DOI":"10.1136\/jitc-2025-012308","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): Current clinical insights, challenges, and future directions","volume":"13","author":"Walton","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(23)00005-0","article-title":"Current drug development and trial designs in neuro-oncology: Report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","volume":"24","author":"Rahman","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_101","first-page":"1155","article-title":"Challenges and Pathways in Regulating Next-Gen Biological Therapies","volume":"27","author":"Agrawal","year":"2025","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Wisdom, A.J., Temple, H., Cui, Y., Del Vecchio, C.T., Kim, T., White, F.M., Floyd, S.R., and Spranger, S. (2026). Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma. Int. J. Radiat. Oncol. Biol. Phys.","DOI":"10.1016\/j.ijrobp.2026.04.013"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuroscience.2026.05.037","article-title":"Understanding resistance in glioblastoma: Insights into personalized and targeted therapeutic strategies","volume":"610","author":"Omran","year":"2026","journal-title":"Neuroscience"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/0113816128367551250703122830","article-title":"Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance","volume":"32","author":"Beylerli","year":"2026","journal-title":"Curr. Pharm. Des."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10555-026-10319-0","article-title":"Dissecting the aberrant vasculature of glioblastoma: Mechanisms and therapeutic targets","volume":"45","author":"Li","year":"2026","journal-title":"Cancer Metastasis Rev."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Salazar-Saura, I., Pinilla-Sala, M., Meg\u00edas, J., Navarro, L., Rosell\u00f3-Sastre, E., and San-Miguel, T. (2024). Pericytes in Glioblastoma: Hidden Regulators of Tumor Vasculature and Therapy Resistance. Cancers, 17.","DOI":"10.3390\/cancers17010015"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2023.1.JNS221798","article-title":"Novel approaches to targeting gliomas at the leading\/cutting edge","volume":"139","author":"Schupper","year":"2023","journal-title":"J. Neurosurg."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1038\/s41467-024-47985-z","article-title":"VC-resist glioblastoma cell state: Vessel co-option as a key driver of chemoradiation resistance","volume":"15","author":"Anezo","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"107922","DOI":"10.1016\/j.pharmthera.2021.107922","article-title":"Genotoxic therapy and resistance mechanism in gliomas","volume":"228","author":"Lang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00066-026-02525-0","article-title":"Interactions and communications in the glioblastoma microenvironment: Potential targets for chemo-\/radiotherapy","volume":"202","author":"Abuhassan","year":"2026","journal-title":"Strahlenther. Onkol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2147\/IJN.S450853","article-title":"Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier","volume":"19","author":"Lim","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"124198","DOI":"10.1016\/j.biomaterials.2026.124198","article-title":"Enhanced delivery of low-density lipoprotein-based nanoparticles to the mouse glioblastoma using focused ultrasound as a novel therapy","volume":"333","author":"Brambila","year":"2026","journal-title":"Biomaterials"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11912-024-01497-7","article-title":"Blood-Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade","volume":"26","author":"Virtanen","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/1878-0261.13678","article-title":"Current status of precision oncology in adult glioblastoma","volume":"18","author":"Weller","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11912-024-01602-w","article-title":"Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?","volume":"26","author":"Alnahhas","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e14000","DOI":"10.1200\/JCO.2026.44.16_suppl.e14000","article-title":"AI\u2013assisted survival prediction in glioma: Meta-analysis of prospective and controlled studies","volume":"44","author":"Kakde","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Cepeda, S., Hernando-P\u00e9rez, E., P\u00e9rez-Riesgo, E., Rodr\u00edguez-Valle, I., Esteban-Sinovas, O., Arrese, I., Lucero-Salaverry, M.M., Zamora, T., Torres-Nieto, M., and Luppino, L.T. (2026). Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial. Neuro Oncol., noag088.","DOI":"10.1093\/neuonc\/noag088"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"120997","DOI":"10.1016\/j.cca.2026.120997","article-title":"Integrating multi-omics data and artificial intelligence for personalized medicine in glioblastoma","volume":"588","author":"Abuhassan","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semcancer.2023.03.006","article-title":"Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma","volume":"91","author":"Luo","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41698-024-00575-0","article-title":"Artificial intelligence in neuro-oncology: Advances and challenges in brain tumor diagnosis, prognosis, and precision treatment","volume":"8","author":"Khalighi","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40001-025-02339-3","article-title":"Predicting survival in malignant glioma using artificial intelligence","volume":"30","author":"Awuah","year":"2025","journal-title":"Eur. J. Med. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:02:08Z","timestamp":1784250128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":121,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142278"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142278","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}